394 related articles for article (PubMed ID: 27772741)
21. Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.
Burkhard A; Toliver J; Rascati K
J Manag Care Spec Pharm; 2021 Jul; 27(7):915-923. PubMed ID: 34185555
[No Abstract] [Full Text] [Related]
22. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
23. Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis.
Li P; Ladage VP; Berger J; Chahin S; Jhaveri M; Geremakis C; Doshi JA
Value Health; 2020 Mar; 23(3):328-334. PubMed ID: 32197728
[TBL] [Abstract][Full Text] [Related]
24. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
25. Clinical and MRI outcomes after stopping or switching disease-modifying therapy in stable MS patients: a case series report.
Berkovich R
Mult Scler Relat Disord; 2017 Oct; 17():123-127. PubMed ID: 29055441
[TBL] [Abstract][Full Text] [Related]
26. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
[TBL] [Abstract][Full Text] [Related]
27. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study.
Nguyen AL; Havrdova EK; Horakova D; Izquierdo G; Kalincik T; van der Walt A; Terzi M; Alroughani R; Duquette P; Girard M; Prat A; Boz C; Sola P; Ferraro D; Lugaresi A; Lechner-Scott J; Barnett M; Grand'Maison F; Grammond P; Ramo-Tello C; Turkoglu R; McCombe P; Pucci E; Trojano M; Granella F; Spitaleri D; Van Pesch V; Soysal A; Oreja-Guevara C; Verheul F; Vucic S; Hodgkinson S; Slee M; Ampapa R; Prevost J; Menoyo JLS; Skibina O; Solaro C; Olascoaga J; Shaw C; Madsen KG; Naidoo K; Hyde R; Butzkueven H; Jokubaitis V;
Mult Scler Relat Disord; 2019 Feb; 28():235-243. PubMed ID: 30623864
[TBL] [Abstract][Full Text] [Related]
28. [The effect of tobacco smoking on clinical effectiveness of immunomodulatory treatment in multiple sclerosis patients].
Jernas Ł; Piorunek T; Tokarz E; Wygladalska-Jernas H; Kozubski W; Michalak S
Przegl Lek; 2012; 69(10):750-2. PubMed ID: 23421025
[TBL] [Abstract][Full Text] [Related]
29. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
30. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
[TBL] [Abstract][Full Text] [Related]
31. Secular trends in disease modifying treatment and expenditure in multiple sclerosis: A longitudinal population study in the north of Ireland.
Cromie D; Mullan F; Hinchliff C; Miller M; McVerry F; McCarron MO
Mult Scler Relat Disord; 2020 Oct; 45():102444. PubMed ID: 32799123
[TBL] [Abstract][Full Text] [Related]
32. Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.
Setayeshgar S; Kingwell E; Zhu F; Zhang X; Zhang T; Marrie RA; Carruthers R; Tremlett H
Mult Scler Relat Disord; 2018 Oct; 25():57-60. PubMed ID: 30036855
[TBL] [Abstract][Full Text] [Related]
33. Adherence and persistence to drug therapies for multiple sclerosis: A population-based study.
Evans C; Marrie RA; Zhu F; Leung S; Lu X; Melesse DY; Kingwell E; Zhao Y; Tremlett H
Mult Scler Relat Disord; 2016 Jul; 8():78-85. PubMed ID: 27456879
[TBL] [Abstract][Full Text] [Related]
34. Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.
Oleen-Burkey M; Cyhaniuk A; Swallow E
BMC Neurol; 2014 Jan; 14():11. PubMed ID: 24423119
[TBL] [Abstract][Full Text] [Related]
35. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
36. Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy.
Curkendall SM; Wang C; Johnson BH; Cao Z; Preblick R; Torres AM; Knappertz V; Gondek K
Clin Ther; 2011 Jul; 33(7):914-25. PubMed ID: 21684600
[TBL] [Abstract][Full Text] [Related]
37. Disparities in DMT treatment: Demographic and neurocognitive differences between MS patients currently treated versus not treated with disease-modifying therapies.
Leavitt VM; Dworkin JD; Galioto R; Ratzan AS
Mult Scler Relat Disord; 2024 May; 85():105508. PubMed ID: 38452646
[TBL] [Abstract][Full Text] [Related]
38. Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis.
Visser LH; van der Zande A
Eur J Neurol; 2011 Nov; 18(11):1343-9. PubMed ID: 21496180
[TBL] [Abstract][Full Text] [Related]
39. Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis.
Nair KV; Corboy J; Kahler K; Allen RR; Ghushcyan V; McQueen RB; Bainbridge J; Dastani H; Mody-Patel N
Expert Rev Neurother; 2011 Jun; 11(6):787-98. PubMed ID: 21651327
[TBL] [Abstract][Full Text] [Related]
40. Medication adherence with disease modifying treatments for multiple sclerosis among US employees.
Kleinman NL; Beren IA; Rajagopalan K; Brook RA
J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
